Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20602581 | 0.86 | EGLN2 (0.31) | EGLN2 | |
| SCHEMBL20602060 | 0.83 | EGLN2 (0.30) | EGLN2 | |
| SCHEMBL20601746 | 0.77 | EGLN2 (0.31) | EGLN2 | |
| SCHEMBL20602570 | 0.77 | — | — | |
| SCHEMBL30241024 | 0.76 | LRRK2 (0.31) | — | |
| SCHEMBL20601733 | 0.76 | LRRK2 (0.31) | — | |
| SCHEMBL20602586 | 0.75 | NOTUM (0.30) | EGLN2 | |
| SCHEMBL20601759 | 0.75 | NOTUM (0.31) | EGLN2 | |
| SCHEMBL20624856 | 0.75 | EGLN2 (0.39) | EGLN2 | |
| SCHEMBL20602035 | 0.74 | CTSK (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3644990-B1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-10981902-B2 | 5-(pyridin-3-yl)oxazole allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981902-B2 | 5-(pyridin-3-yl)oxazole allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3644990-A1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | Merck Sharp & Dohme Corp. (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200109137-A1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200109137-A1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2020-04-09 | — | — | US | disclosed |
| WO-2019005589-A1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019000238-A1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019005589-A1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109137-A1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | CHRM5, CHRM4, CHRM3 | EGLN2 4885/4885 |
| US-10981902-B2 | 5-(pyridin-3-yl)oxazole allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM5, CHRM4, CHRM3 | EGLN2 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.